Hanssens Laurence S, Mulier Sandra F
Service de Pneumologie-Allergologie, Centre de reference de Mucoviscidose de l'ULB, Hôpital Universitaire des Enfants Reine Fabiola.
J Pharm Belg. 2007;62(1):33-7.
Asthma is a chronic inflammatory disorder of the airways with an impact on the life of the patient, his family and the society. Asthma is the most common chronic disease of the childhood. Consequently, prevention and treatment of asthma are real challenges in public health. Treatment includes two levels: prevention and medication treatment. Prevention is to avoid one or several causes of asthma and risk factors of exacerbations particularly in high risk population. Medication treatment includes the reliever treatment and the maintenance treatment. Bronchodilatator treatment will be used in first line treatment in asthma attacks. Inhaled glucocorticosteroids are the most effective controller medications. No treatment is curative for asthma, establishing of therapeutic objectives is necessary. The reliever treatment, the maintenance treatment, the new classification of asthma and the new recommendations of therapeutic management will be discussed.
哮喘是一种气道慢性炎症性疾病，会对患者及其家庭和社会生活产生影响。哮喘是儿童期最常见的慢性病。因此，哮喘的预防和治疗是公共卫生领域的实际挑战。治疗包括两个层面：预防和药物治疗。预防是指避免一种或几种哮喘病因以及加重发作的危险因素，尤其是在高危人群中。药物治疗包括缓解治疗和维持治疗。支气管扩张剂治疗将用于哮喘发作的一线治疗。吸入性糖皮质激素是最有效的控制药物。目前尚无治愈哮喘的疗法，因此有必要确立治疗目标。本文将讨论缓解治疗、维持治疗、哮喘的新分类以及治疗管理的新建议。
